Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Response variability to P2Y12 receptor inhibitors: expectations and reality.

Siller-Matula JM, Trenk D, Schrör K, Gawaz M, Kristensen SD, Storey RF, Huber K; EPA (European Platelet Academy).

JACC Cardiovasc Interv. 2013 Nov;6(11):1111-28. doi: 10.1016/j.jcin.2013.06.011. Review.

PMID:
24262612
[PubMed - indexed for MEDLINE]
2.

PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity.

Li X, Zhang L, Chen X, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Xu Q, Zhang Y, Li Y, Lu C, Yin T.

Thromb Res. 2013 Oct;132(4):444-9. doi: 10.1016/j.thromres.2013.08.004. Epub 2013 Aug 9.

PMID:
23993903
[PubMed - indexed for MEDLINE]
3.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
[PubMed - indexed for MEDLINE]
4.

P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.

Zoheir N, Abd Elhamid S, Abulata N, El Sobky M, Khafagy D, Mostafa A.

Blood Coagul Fibrinolysis. 2013 Jul;24(5):525-31. doi: 10.1097/MBC.0b013e32835e98bf.

PMID:
23751603
[PubMed - indexed for MEDLINE]
5.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
[PubMed - indexed for MEDLINE]
6.

Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.

Franken CC, Kaiser AF, Krüger JC, Overbeck K, Mügge A, Neubauer H.

Thromb Haemost. 2013 Jul;110(1):131-40. doi: 10.1160/TH13-01-0021. Epub 2013 Apr 25.

PMID:
23615745
[PubMed - indexed for MEDLINE]
7.

Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".

Alexopoulos D, Xanthopoulou I.

Circ Cardiovasc Interv. 2013 Feb;6(1):e11. doi: 10.1161/CIRCINTERVENTIONS.112.975953. No abstract available.

PMID:
23424274
[PubMed - indexed for MEDLINE]
Free Article
8.

The impact of CYP2C19 genotype on cardiovascular events and platelet reactivity in patients with coronary artery disease receiving clopidogrel.

Tousoulis D, Siasos G, Zaromitidou M, Oikonomou E, Maniatis K, Kioufis S, Kokkou E, Papavassiliou AG, Stefanadis C.

Int J Cardiol. 2013 Sep 30;168(2):1594-6. doi: 10.1016/j.ijcard.2013.01.040. Epub 2013 Feb 10. No abstract available.

PMID:
23402725
[PubMed - indexed for MEDLINE]
9.

Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro PJ, Saut N, Gaborit B, Pankert M, Cohen W, Lambert M, Beguin S, Morange PE, Bonnet JL, Alessi MC, Cuisset T.

Am J Cardiol. 2013 Apr 1;111(7):985-90. doi: 10.1016/j.amjcard.2012.12.013. Epub 2013 Jan 19.

PMID:
23340030
[PubMed - indexed for MEDLINE]
10.

Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.

Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL 3rd, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB; SWAP Investigators.

Thromb Haemost. 2013 Feb;109(2):347-55. doi: 10.1160/TH12-06-0378. Epub 2012 Dec 6.

PMID:
23223867
[PubMed - indexed for MEDLINE]
11.

Clinical impact of genetically determined platelet reactivity.

Laine M, Arméro S, Peyrol M, Sbragia P, Thuny F, Paganelli F, Bonello L.

J Cardiovasc Transl Res. 2013 Jun;6(3):398-403. doi: 10.1007/s12265-012-9421-4. Epub 2012 Nov 13. Review.

PMID:
23149816
[PubMed - indexed for MEDLINE]
12.

Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.

Amoah V, Storey RF, Worrall AP, Goodridge K, Lovatt T, Smallwood A, Armesilla AL, Nevill AM, Cotton JM.

Platelets. 2013;24(8):643-8. doi: 10.3109/09537104.2012.733046. Epub 2012 Nov 13.

PMID:
23148794
[PubMed - indexed for MEDLINE]
13.

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F.

Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9.

PMID:
23048056
[PubMed - indexed for MEDLINE]
Free Article
14.

Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China.

Wu H, Qian J, Xu J, Sun A, Sun W, Wang Q, Ge J.

Pharmacogenet Genomics. 2012 Dec;22(12):887-90. doi: 10.1097/FPC.0b013e328359253a.

PMID:
22990067
[PubMed - indexed for MEDLINE]
15.
16.

Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis.

Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M.

Platelets. 2013;24(5):352-61. doi: 10.3109/09537104.2012.700969. Epub 2012 Jul 3. Review.

PMID:
22757746
[PubMed - indexed for MEDLINE]
17.

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?

Laine M, Camoin-Jau L, Bessereau J, Sébastien A, Paganelli F, Bonello L.

Curr Pharm Des. 2012;18(33):5392-401. Review.

PMID:
22724420
[PubMed - indexed for MEDLINE]
18.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
[PubMed - indexed for MEDLINE]
19.

Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.

Würtz M, Grove EL.

Curr Pharm Des. 2012;18(33):5344-61. Review.

PMID:
22724409
[PubMed - indexed for MEDLINE]
20.

Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.

Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ; GIFT Investigators.

J Am Coll Cardiol. 2012 May 29;59(22):1928-37. doi: 10.1016/j.jacc.2011.11.068.

PMID:
22624833
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk